🧬 Combination Amyloid-Tau Therapy Strategy Simulator

Amyloid-Tau Interaction Hypothesis

Amyloid plaques may drive downstream tau pathology spread.

• Upstream: Amyloid cascade (placeholder fact)
• Downstream: Tau spread (placeholder fact)
• Early stage: Interaction window (placeholder fact)
• Preclinical: Evidence base (placeholder fact)

Biological rationale for dual targeting

Placeholder: amyloid may trigger and accelerate tau pathology spread.

Placeholder highlight: interaction hypothesis motivates combination approach.

Sequential vs Simultaneous Dosing

Comparing anti-amyloid-first sequencing against simultaneous dual dosing.

• Amyloid→Tau: Sequential arm (placeholder fact)
• Both agents: Simultaneous arm (placeholder fact)
• Variable: Washout period (placeholder fact)
• Continuous: Safety monitoring (placeholder fact)

Dosing order considerations

Placeholder: sequencing may affect combined safety and efficacy outcomes.

Placeholder highlight: dosing order remains an open design question.

Dual-Target Trial Design

Trial architecture needed to evaluate combined dual-target therapy.

• 4-arm factorial: Arms (placeholder fact)
• Placeholder: Enrollment target (placeholder fact)
• 18-24 months: Duration (placeholder fact)
• Cognitive + biomarker: Endpoint type (placeholder fact)

Factorial trial architecture

Placeholder: factorial design isolates individual and combined effects.

Placeholder highlight: dual-target trials require larger sample sizes.

Combined Biomarker Monitoring

Monitoring amyloid and tau biomarkers jointly across treatment.

• PET / CSF: Amyloid marker (placeholder fact)
• PET / p-tau217: Tau marker (placeholder fact)
• Periodic: Sampling frequency (placeholder fact)
• Dual panel: Panel breadth (placeholder fact)

Dual biomarker panel rationale

Placeholder: joint biomarker tracking clarifies mechanism-specific response.

Placeholder highlight: combined panels detect divergent target engagement.

Additive vs Synergistic Outcome Assessment

Statistical models distinguish additive from synergistic combined benefit.

• Sum of effects: Additive model (placeholder fact)
• Interaction term: Synergy model (placeholder fact)
• Interaction ANOVA: Statistical test (placeholder fact)
• Cognitive decline: Outcome measure (placeholder fact)

Distinguishing additive from synergistic effects

Placeholder: interaction term testing separates additive from synergistic gains.

Placeholder highlight: synergy would exceed sum of monotherapy effects.